Remmele Julia, Helm Paul C, Li Jia, Oberhoffer-Fritz Renate, Bauer Ulrike M M, Ewert Peter
Department of Congenital Heart Disease and Pediatric Cardiology, German Heart Center Munich, Technical University of Munich, Munich, Germany.
Institute of Preventive Pediatrics, Department of Health and Sport Sciences, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.
Cardiovasc Diagn Ther. 2024 Dec 31;14(6):1108-1121. doi: 10.21037/cdt-24-302. Epub 2024 Dec 9.
Patients with congenital heart defects (CHDs) are at higher risk for infectious diseases. This may partly be due to frequent hospital stays and the associated exposure to pathogens. This study aims to provide a comprehensive overview of immunisation coverage among twins in which at least one twin has CHD. Confounding factors from shared environments and genetic components can be controlled through co-twin control analysis, thus minimising confounding effects.
In the framework of the cross-sectional twin study "Same Same, but different?" twins, with at least one of them having CHD aged 3 to 99 years, were recruited nationwide in Germany between August 2019 and December 2022. Their primary immunisation status based on the German Standing Committee on Vaccination (STIKO) and immunisation against respiratory diseases, including influenza, respiratory syncytial virus (RSV), pneumococci, and coronavirus disease 2019 (COVID-19), were assessed and compared between the twins.
In total, 64 twins (128 individuals) were included for direct twin comparison. Overall, 56.3% of the twins reached complete primary immunisation status, negatively influenced by hospitalisation duration [odds ratio (OR): 0.98; 95% confidence interval (CI): 0.96-0.99; P=0.01]. Compared to their healthy twin, twins with CHD received their rotavirus vaccine significantly later (P=0.04). Only 3.1% of the twins with CHD received the pneumococcal vaccine recommended for high-risk patients. A higher number of catheter interventions can lead to a higher number of patients receiving the pneumococcal vaccine (OR: 1.79; 95% CI: 1.16-2.76; P=0.009). The direct twin comparison showed a significant difference between the twins in vaccination against influenza (P=0.007), although it is recommended for CHD patients and their household contacts-including their twin. A higher number of surgeries (OR: 1.51; 95% CI: 1.12-2.05; P=0.007) and catheter interventions (OR: 1.49; 95% CI: 1.00-2.21; P=0.049) increase the probability of influenza vaccination in CHD patients.
In the direct twin comparison, twins are similarly vaccinated except for RSV and influenza. Immunisation against influenza in twins should be improved. With new upcoming RSV vaccines, existing recommendations must be reconsidered and adapted. Another disturbing fact is that only 30% of infants are vaccinated against pertussis and pneumococcus within the primary recommended timeframe, even though they are exposed at high risk during infancy. Further education of parents, patients, and medical staff might lead to higher vaccination coverage, especially in pneumococcal vaccines recommended for high-risk patients. We must provide sufficient information on the importance of vaccinations and their side effects for parents' and patients' decision-making.
先天性心脏病(CHD)患者患传染病的风险更高。这可能部分归因于频繁住院以及由此带来的病原体接触。本研究旨在全面概述至少有一名双胞胎患有CHD的双胞胎群体的免疫接种覆盖率。通过双胞胎对照分析,可以控制来自共同环境和遗传因素的混杂因素,从而最大限度地减少混杂效应。
在横断面双胞胎研究“相同却又不同?”的框架下,于2019年8月至2022年12月在德国全国范围内招募年龄在3至99岁、至少有一人患有CHD的双胞胎。根据德国疫苗接种常设委员会(STIKO)评估他们的基础免疫状况,并比较双胞胎之间针对包括流感、呼吸道合胞病毒(RSV)、肺炎球菌和2019冠状病毒病(COVID-19)在内的呼吸道疾病的免疫接种情况。
总共纳入64对双胞胎(128人)进行直接双胞胎比较。总体而言,56.3%的双胞胎达到了完全基础免疫状态,住院时间对此有负面影响[比值比(OR):0.98;95%置信区间(CI):0.96 - 0.99;P = 0.01]。与健康的双胞胎相比,患有CHD的双胞胎接种轮状病毒疫苗的时间明显更晚(P = 0.04)。只有3.1%患有CHD的双胞胎接种了针对高危患者推荐的肺炎球菌疫苗。更多的导管介入操作会导致更多患者接种肺炎球菌疫苗(OR:1.79;95% CI:1.16 - 2.76;P = 0.009)。直接双胞胎比较显示,双胞胎之间在流感疫苗接种方面存在显著差异(P = 0.007),尽管流感疫苗是推荐给CHD患者及其家庭接触者(包括其双胞胎)的。更多的手术(OR:1.51;95% CI:1.12 - 2.05;P = 0.007)和导管介入操作(OR:1.49;95% CI:1.00 - 2.21;P = 0.049)会增加CHD患者接种流感疫苗的概率。
在直接双胞胎比较中,除了RSV和流感疫苗外,双胞胎的疫苗接种情况相似。双胞胎的流感疫苗接种情况有待改善。随着新型RSV疫苗的出现,必须重新考虑并调整现有建议。另一个令人不安的事实是,即使婴儿在婴儿期处于高风险暴露状态,只有30%的婴儿在主要推荐时间范围内接种了百日咳和肺炎球菌疫苗。对家长、患者和医护人员进行进一步教育可能会提高疫苗接种覆盖率,特别是在针对高危患者推荐的肺炎球菌疫苗方面。我们必须提供足够的关于疫苗接种重要性及其副作用的信息,以便家长和患者做出决策。